Copyright © 2001 by the European Society of Cardiology.
A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study
a University Hospital Gasthuisberg, Leuven, Belgium
b Hôpital Saint-Jacques, Besançon, France
c A.Z. Middelheim, Antwerpen, Belgium
d Z.O.L. Campus St. Jan, Genk, Belgium
e C.H.R. de la Citadelle, Liège, Belgium
f C.H.U. De Caen, Caen, France
g Catharina Ziekenhuis, Eindhoven, The Netherlands
h Hôpital Tenon, Paris, France
i Imelda Ziekenhuis, Bonheiden, Belgium
j Medizinische Klinik III, Mainz, Germany
revised April 24, 2001; accepted April 25, 2001
Abstract
Background ORG31540/SR90107A, a synthetic pentasaccharide, is a selective inhibitor of factor-Xa. It was hypothesized that prolonged factor-Xa inhibition with pentasaccharide may be an effective and safe antithrombotic co-therapy in acute myocardial infarction.
Methods and Results Patients (n=333) with evolving ST-segment elevation acute myocardial infarction were treated with aspirin and alteplase and randomized to unfractionated heparin, given intravenously during 48 to 72h, or to a low, medium or high dose of pentasaccharide, administered daily for 5 to 7 days, intravenously on the first day, then subcutaneously. Coronary angiography was performed at 90min and on days 5 to 7. Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 rates at 90min were similar in the four treatment groups. Among patients with TIMI 3 flow at 90min and who did not undergo a coronary intervention (n=155), a trend towards less reocclusion of the infarct-related vessel on days 5 to 7 was observed with pentasaccharide: 0·9% vs 7·0% with unfractionated heparin (P=0·065). Also, fewer revascularizations during the 30-day follow-up period were performed in patients given pentasaccharide (39% vs 51% for unfractionated heparin;P=0·054). The primary safety end-point, the combined incidence of intracranial haemorrhage and need for blood transfusion, was identical with pentasaccharide and unfractionated heparin (7·1%). One non-fatal intracranial haemorrhage occurred in the 241 patients given pentasaccharide (0·4%).
Conclusions In this study, pentasaccharide given together with alteplase was safe and as effective as unfractionated heparin in restoring coronary artery patency. Prolonged administration of pentasaccharide was associated with a trend towards less reocclusion and fewer revascularizations. Selective factor-Xa-inhibition seems to be an attractive therapeutic concept in patients presenting with ST-segment elevation acute myocardial infarction.
Key Words: Fibrinolysis, heparin, myocardial infarction, reperfusion
f1 Correspondence: Frans Van de Werf, MD, PhD, Chairman, Department of Cardiology, U.Z. Gasthuisberg, University of Leuven, Herestraat 49, B-3000 Leuven, Belgium.
References
- de Bono DP, Simoons ML, Tijsen J. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J. 1992;67:122–128
[Abstract/Free Full Text] - Lancet. 1990;336:71–75[CrossRef][Web of Science][Medline]
- Lancet. 1994;343:311–322[CrossRef][Web of Science][Medline]
- Hirsch J. Heparin. N Engl J Med. 1991;324:1565–1574[Web of Science][Medline]
- Herbert JM, Petitou M, Lormeau JC. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Reviews. 1997;15:1–26
- Walenga J, Jeske W, Bara L. Biochemical and pharmacological rationale for the development of a synthetic heparin pentasaccharide. Thromb Res. 1997;86:1–36[CrossRef][Web of Science][Medline]
- Hemker H, Choay J, Beguin S. Free factor Xa is on the main pathway of thrombin generation in clotting plasma. Bioch Biophys Acta. 1989;992:409–411[Medline]
- Visser A, Meuleman D. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans. Thromb Res. 1990;58:469–474[CrossRef][Web of Science][Medline]
- Vogel G, van Amsterdam R, Kop W. Pentasaccharide and OrgaranTM arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemostas. 1993;69:29–34[Web of Science][Medline]
- Boneu B, Necciari J, Cariou R. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107A/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost. 1995;74:1468–1473[Web of Science][Medline]
- Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 2001;344:619–625
[Abstract/Free Full Text] - Lassen MR. The Ephesus Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood. 2000;96:490a
- Bauer K. The Pentamaks Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thrombo embolism (VTE) after elective major knee surgery. Blood. 2000;96:490a
- Eriksson B. The Penthifra Study. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thrombo embolism (VTE) after hip fracture surgery. Blood. 2000;96:490a
- Turpie G. The Pentathlon 2000 Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thrombo embolism (VTE) after elective hip replacement surgery. Blood. 2000;96:491a
- Vuillemenot A, Schiele F, Meneveau N. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent. A pilot study in the setting of coronary angioplasty. Thromb Haemost. 1999;81:214–220[Web of Science][Medline]
- Pislaru S, Pislaru C, Zhu X. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis. Thromb Haemost. 1998;79:1130–1135[Web of Science][Medline]
- Chesebro JH, Knatterud G, Roberts R. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76:142–154
[Abstract/Free Full Text] - N Engl J Med. 1993;329:673–682
[Abstract/Free Full Text] - N Engl J Med. 1993;329:1615–1622
[Abstract/Free Full Text] - Rao AK, Pratt C, Berke A. Thrombolysis in Myocardial Infarction (TIMI) Trial Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11[Abstract]
- Cairns JA, Kennedy JW, Fuster V. Fifth ACCP Consensus Conference on Antithrombotic Therapy. Coronary Thrombolysis. Chest. 1998;114:634S–657S
[Free Full Text] - Topol EJ, George BS, Kereiakes. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation. 1989;79:281–286
[Abstract/Free Full Text] - Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:1412–1417[CrossRef][Web of Science][Medline]
- Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1990;323:1433–1437[Abstract]
- Ross AM, Molhoek GP, Knudtson ML. A randomized comparison of low-molecular-weight heparin and unfractionated heparin adjunctive to t-PA thrombolysis and aspirin (HART-II). Circulation. 2000;102:II-600
- Wallentin, L, The ASSENT-Plus Study. A comparison of dalteparin and unfractionated heparin as adjunct to t-PA
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G.G. Turpie Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C1 - C7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
 |
|
 The Fifth Organization to Assess Strategies in Acu Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes N. Engl. J. Med., April 6, 2006; 354(14): 1464 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Additional Information JAMA, March 15, 2006; 295(11): E1 - E6. [Full Text] [PDF]
|
|
|
|
 |
|
 V Pengo New trends in anticoagulant treatments Lupus, September 1, 2005; 14(9): 789 - 793. [Abstract] [PDF]
|
|
|
|
 |
|
 R Katira, A Chauhan, and R S More Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation Postgrad. Med. J., June 1, 2005; 81(956): 370 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Mehta, P. G. Steg, C. B. Granger, J.-P. Bassand, D. P. Faxon, J. I. Weitz, R. Afzal, B. Rush, R. J.G. Peters, M. K. Natarajan, et al. Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention: Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial Circulation, March 22, 2005; 111(11): 1390 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hirsh, M. O'Donnell, and J. I. Weitz New anticoagulants Blood, January 15, 2005; 105(2): 453 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Savi, B. H. Chong, A. Greinacher, Y. Gruel, J. G. Kelton, T. E. Warkentin, P. Eichler, D. Meuleman, M. Petitou, J.-P. Herault, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin Blood, January 1, 2005; 105(1): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Wiggins and S. Spinler Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes Journal of Pharmacy Practice, October 1, 2004; 17(5): 347 - 369. [Abstract] [PDF]
|
|
|
|
|
|
J. I. Weitz, J. Hirsh, and M. M. Samama New Anticoagulant Drugs: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 265S - 286S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P R Sinnaeve and F J Van de Werf Will oral antithrombin agents replace warfarin? Heart, August 1, 2004; 90(8): 827 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F Viles-Gonzalez, V. Fuster, and J. J Badimon Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences Eur. Heart J., July 2, 2004; 25(14): 1197 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Simoons, I. W. G. Bobbink, J. Boland, M. Gardien, P. Klootwijk, A. W. A. Lensing, W. Ruzyllo, V. A. W. M. Umans, A. Vahanian, F. Van De Werf, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) study J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2183 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Weitz, S. Middeldorp, W. Geerts, and J. A. Heit Thrombophilia and New Anticoagulant Drugs Hematology, January 1, 2004; 2004(1): 424 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Bauer New Pentasaccharides for Prophylaxis of Deep Vein Thrombosis: Pharmacology Chest, December 1, 2003; 124 (2009): 364S - 370S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. G. Turpie, B. I. Eriksson, K. A. Bauer, and M. R. Lassen New Pentasaccharides for the Prophylaxis of Venous Thromboembolism: Clinical Studies Chest, December 1, 2003; 124 (2009): 371S - 378S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Tran and G. Lee Fondaparinux for Prevention of Venous Thromboembolism in Major Orthopedic Surgery Ann. Pharmacother., November 1, 2003; 37(11): 1632 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bates and J. I. Weitz Emerging Anticoagulant Drugs Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1491 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. M. Moons, R. J. G. Peters, N. R. Bijsterveld, J. J. Piek, M. H. Prins, G. P. Vlasuk, W. E. Rote, and H. R. Buller Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplastyAppendix J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2147 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cohen The role of low-molecular-weight heparin in the management of acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 55S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Alving, C. W. Francis, W. R. Hiatt, and M. R. Jackson Consultations on Patients with Venous or Arterial Diseases Hematology, January 1, 2003; 2003(1): 540 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Bijsterveld, A. H. Moons, S. M. Boekholdt, B. E. van Aken, H. Fennema, R. J.G. Peters, J. C.M. Meijers, H. R. Buller, and M. Levi Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers Circulation, November 12, 2002; 106(20): 2550 - 2554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Brouwer, P. J.P.C. van den Bergh, W. R.M. Aengevaeren, G. Veen, H. E. Luijten, D. P. Hertzberger, A. J. van Boven, R. P.J.W. Vromans, G. J.H. Uijen, and F. W.A. Verheugt Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction: Results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial Circulation, August 6, 2002; 106(6): 659 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.L. Simoons, M. Krzeminska-Pakula, A. Alonso, S.G. Goodman, A. Kali, U. Loos, F. Gosset, V. Louer, and F. Bigonzi Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study Eur. Heart J., August 2, 2002; 23(16): 1282 - 1290. [Abstract] [PDF]
|
|
|
|
|
|
C. K. Dyke, R. C. Becker, N. S. Kleiman, J. S. Hochman, E. G. Bovill, A. M. Lincoff, G. Gerstenblith, V. Dzavik, L. H. Gardner, V. Hasselblad, et al. First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation Circulation, May 21, 2002; 105(20): 2385 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.J. Van de Werf, E.M. Antman, and M.L. Simoons Managing ST elevation myocardial infarction Eur. Heart J. Suppl., May 1, 2002; 4(suppl_E): E15 - E23. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Brouwer and F. W.A. Verheugt Oral Anticoagulation for Acute Coronary Syndromes Circulation, March 19, 2002; 105(11): 1270 - 1274. [Full Text] [PDF]
|
|
|
|
 |
|
 Synthetic Pentasaccharide Enhances Fibrinolysis in Acute MI Journal Watch Cardiology, November 30, 2001; 2001(1130): 4 - 4. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||